Autologous umbilical cord blood transfusion in young children with type 1 diabetes fails to preserve C-peptide.

ABSTRACT:

Objective

We conducted an open-label, phase I study using autologous umbilical cord blood (UCB) infusion to ameliorate type 1 diabetes (T1D). Having previously reported on the first 15 patients reaching 1 year of follow-up, herein we report on the complete cohort after 2 years of follow-up.

Research design and methods

A total of 24 T1D patients (median age 5.1 years) received a single intravenous infusion of autologous UCB cells and underwent metabolic and immunologic assessments.

Results

No infusion-related adverse events were observed. β-Cell function declined after UCB infusion. Area under the curve C-peptide was 24.3% of baseline 1 year postinfusion (P < 0.001) and 2% of baseline 2 years after infusion (P < 0.001). Flow cytometry revealed increased regulatory T ce

SUBMITTER: Haller MJ 

PROVIDER: S-EPMC3220832 | biostudies-literature | 2011 Dec

REPOSITORIES: biostudies-literature